Amphastar Pharmaceuticals, Inc. - Common Stock (NQ:AMPH)

25.43 +0.08 (+0.32%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Amphastar Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

agilon health, LifeStance Health Group, The Pennant Group, Corcept, and Amphastar Pharmaceuticals Shares Plummet, What You Need To Know

July 18, 2025

A number of healthcare stocks fell in the afternoon session after several negative developments weighed on the sector. Weakness in managed care providers was a significant factor, with companies like...

Via StockStory

Topics Lawsuit World Trade

Amphastar Pharmaceuticals Aims to Quadruple Domestic Manufacturing Capacity at Rancho Cucamonga Headquarters

July 14, 2025

Via ACCESS Newswire

Acadia Healthcare, 10x Genomics, Amphastar Pharmaceuticals, Myriad Genetics, and QuidelOrtho Stocks Trade Down, What You Need To Know

July 11, 2025

A number of stocks fell in the afternoon session after the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada.

Via StockStory

Topics ETFs Stocks World Trade

Earnings Scheduled For May 7, 2025 ↗

May 07, 2025

Via Benzinga

Earnings Outlook For Amphastar Pharma ↗

May 06, 2025

Via Benzinga

1 Healthcare Stock on Our Buy List and 2 to Approach with Caution

July 11, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But speed bumps such as inventory destockings have persisted in the wake of COVID-19,...

Via StockStory

Topics Stocks

AMPHASTAR PHARMACEUTICALS INC (NASDAQ:AMPH) – An Undervalued Stock Worth Considering ↗

July 05, 2025

AMPH ASTAR PHARMACEUTICALS (NASDAQ:AMPH) presents an undervalued opportunity with strong profitability, reasonable financial health, and historical growth, making it a candidate for value investors.

Via Chartmill

1 Healthcare Stock with Solid Fundamentals and 2 to Ignore

June 30, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory...

Via StockStory

Topics Stocks

3 Value Stocks with Questionable Fundamentals

June 24, 2025

The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued...

Via StockStory

AMPHASTAR PHARMACEUTICALS INC (NASDAQ:AMPH) – An Undervalued Stock Worth Considering ↗

June 12, 2025

AMPH ASTAR PHARMACEUTICALS INC (NASDAQ:AMPH) is an undervalued stock with strong profitability, reasonable financial health, and an attractive valuation, making it a candidate for value investors.

Via Chartmill

3 Russell 2000 Stocks with Questionable Fundamentals

June 11, 2025

Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resources than their bigger counterparts, these...

Via StockStory

3 Small-Cap Stocks Walking a Fine Line

May 29, 2025

Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street. Many opportunities exist in this part of the market, but it is also a...

Via StockStory

Evolent Health, Amphastar Pharmaceuticals, Iridium, and Magnite Stocks Trade Up, What You Need To Know

May 27, 2025

A number of stocks jumped in the afternoon session after the major indices rebounded (Nasdaq +2.0%, S&P 500 +2.0%) as President Trump postponed the planned 50% tariff on European Union imports,...

Via StockStory

Topics Artificial Intelligence Government Stocks

Generic Pharmaceuticals Stocks Q1 In Review: Amphastar Pharmaceuticals (NASDAQ:AMPH) Vs Peers

May 22, 2025

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Amphastar Pharmaceuticals (NASDAQ:AMPH) and its peers.

Via StockStory

Topics Artificial Intelligence Intellectual Property

Amphastar Pharmaceuticals to Present at the Jefferies Global Healthcare Conference

May 22, 2025

Via ACCESS Newswire

AMPHASTAR PHARMACEUTICALS INC (NASDAQ:AMPH) – A Potentially Undervalued Stock Worth Watching ↗

May 17, 2025

AMPH ASTAR PHARMACEUTICALS INC (NASDAQ:AMPH) offers strong profitability and an undervalued stock price, making it a candidate for value investors. Check the full analysis for details.

Via Chartmill

This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday ↗

May 12, 2025

Via Benzinga

Amphastar Pharmaceuticals to Present at the 2025 Bank of America Health Care Conference

May 09, 2025

Via ACCESS Newswire

Amphastar Pharmaceuticals (NASDAQ:AMPH) Misses Q1 Sales Targets

May 07, 2025

Pharmaceutical company Amphastar Pharmaceuticals (NASDAQAMPH) fell short of the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $170.5 million. Its non-GAAP profit of $0.74...

Via StockStory

Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2025

May 07, 2025

Via ACCESS Newswire

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH): A Closer Look at Dividend Potential ↗

May 01, 2025

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH): A Closer Look at Dividend Potential

Via Chartmill

Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 7th, 2025

April 30, 2025

Via ACCESS Newswire

2 Healthcare Stocks on Our Watchlist and 1 to Be Wary Of

April 29, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory...

Via StockStory

Topics Stocks

Generic Pharmaceuticals Stocks Q4 Teardown: Viatris (NASDAQ:VTRS) Vs The Rest

April 28, 2025

Let’s dig into the relative performance of Viatris (NASDAQ:VTRS) and its peers as we unravel the now-completed Q4 generic pharmaceuticals earnings season.

Via StockStory

Topics Artificial Intelligence Intellectual Property

AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) is an undervalued gem with solid fundamentals. ↗

April 25, 2025

Uncover the potential of AMPHASTAR PHARMACEUTICALS IN, an undervalued stock. NASDAQ:AMPH maintains a strong financial position and offers an appealing valuation.

Via Chartmill

2 Safe-and-Steady Stocks with Solid Fundamentals and 1 to Think Twice About

April 24, 2025

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Via StockStory

2 Reasons to Like AMPH and 1 to Stay Skeptical

April 15, 2025

What a brutal six months it’s been for Amphastar Pharmaceuticals. The stock has dropped 50.3% and now trades at $24.50, rattling many shareholders. This was partly due to its softer quarterly results...

Via StockStory

Topics Supply Chain

Amphastar Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference

April 03, 2025

Via ACCESS Newswire

International Medication Systems, Ltd. Receives FDA's Drug Shortage Assistance Award

March 28, 2025

Via ACCESS Newswire

AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH), an undervalued stock with good fundamentals. ↗

March 27, 2025

Take a closer look at AMPHASTAR PHARMACEUTICALS IN , a remarkable value stock. NASDAQ:AMPH excels in fundamentals and maintains a very reasonable valuation.

Via Chartmill

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.